['prostate cancer']
['apalutamide', 'placebo', 'androgen deprivation therapy (adt)']

        Inclusion Criteria:

          -  Diagnosis of prostate adenocarcinoma as confirmed by the investigator

          -  Metastatic disease documented by greater than or equal to (>=) 1 bone lesions on 99mTc
             bone scan. Participants with a single bone lesion must have confirmation of bone
             metastasis by computed tomography (CT) or magnetic resonance imaging (MRI)

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade of 0 or 1

          -  Participants who received docetaxel treatment must meet the following criteria: a)
             Received a maximum of 6 cycles of docetaxel therapy for mHSPC; b) Received the last
             dose of docetaxel <=2 months prior to randomization; c) Maintained a response to
             docetaxel of stable disease or better, by investigator assessment of imaging and PSA,
             prior to randomization

          -  Other allowed prior treatment for mHSPC: a) Maximum of 1 course of radiation or
             surgical intervention; radiation therapy for metastatic lesions must be completed
             prior to randomization; b) Less than or equal to (<=) 6 months of ADT prior to
             randomization

          -  Allowed prior treatments for localized prostate cancer (all treatments must have been
             completed >= 1 year prior to randomization) a) <= 3 years total of ADT; b) All other
             forms of prior therapies including radiation therapy, prostatectomy,lymph node
             dissection, and systemic therapies

        Exclusion Criteria:

          -  Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of
             the prostate

          -  Known brain metastases

          -  Lymph nodes as only sites of metastases

          -  Visceral (ie, liver or lung) metastases as only sites of metastases

          -  Other prior malignancy less than or equal to 5 years prior to randomization with the
             exception of squamous or basal cell skin carcinoma or non-invasive superficial bladder
             cancer

          -  Prior treatment with other next generation anti-androgens or other CYP17 inhibitors,
             immunotherapy or radiopharmaceutical agents for prostate cancer

          -  History of seizures or medications known to lower seizure threshold
      